Effect of Gluten-Free Diet on Cerebellar MR Spectroscopy in Gluten Ataxia
Neurol 89:705-709, Hadjivassiliou, M.,et al, 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?
NEJM 377:411-414, Goodman, C.W. & Brett, A.S., 2017
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
NEJM 377:431-441, Pollack, C.V.,et al, 2017
CT Angiography ASPECTS Predicts Outcome Much Better Than Noncontrast CT in Patients with Stroke Treated Endovascularly
AJNR 38:1569-1573, Sallustio, F.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Overview of IgG4-related Disease
UptoDate, July, Moutsopoulos,H.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
A Case of Altered Mental Status, Not Otherwise Specified
Neurol 89:e154-e158, Swor, D.E.,et al, 2017
Thalamic Deep Brain Stimulation for Tremor in Parkinson Disease, Essential Tremor, and Dystonia
Neurol 89:1416-1423, Cury, R.G.,et al, 2017
Diagnostic Challenges in a Young Patient with Hypereosinophilia
Neurol 89:e159-e165, Ortiz, J.G.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017
Zolpidem for the Treatment of Neurologic Disorders
JAMA Neurol 74:1130-1139, Bomalaski, M.N.,et al, 2017
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Chess Study Revives Debate Over Cognition-Enhancing Drugs
JAMA doi:10.1001/JAMA:2017.8114, Lyon, J., 2017
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Ann Neurol 81:849-856, Lansberg, M.G.,et al, 2017
Subarachnoid Hemorrhage
NEJM 377:257-266, Lawton, M.T. & Vates, G.E., 2017
Interim Results from the CATNON trial (EORTC study 260-53-22054) of treatment with Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study
Lancet 390:1645-1653, Van Den Bent, M.J.,et al, 2017
Neuroimaging Changes in Menkes Disease, Part 1
AJNR 38:1850-1857, Manara, R.,et al, 2017
Intrathecal 2-hydroxypropyl-�-cyclodextrin Decreases Neurological Disease Progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial
Lancet 390:1758-1768, Ory, D.S.,et al, 2017
Short-Course Radiation Plus Temozolomide in Elderly Patients with Glioblastoma
NEJM 376:1027-1037, Perry, J.R.,et al, 2017
Clinicopathologic Conference, Primary Adrenal Insufficiency (Addisons Disease)
NEJM 376:1159-1167, Case 9-2017, 2017
Management of Sciatica
NEJM 376:1175-1177, Ramaswami, Ramya, 2017
Trial of Pregabalin for Acute and Chronic Sciatica
NEJM 376:1111-1120, Mathieson, S.,et al, 2017
Optimal Timing of Anticoagulant Treatment after Intracerebral Hemorrhage in Patients with Atrial Fibrillation
Stroke 48:314-320, Pennlert, J.,et al, 2017
Successful Management of Super-Refractory Status Epilepticus with Thalamic Deep Brain Stimulation
Ann Neurol 81:142-146, Lehtimaki, K.,et al, 2017
A 35-year-old Woman with Hyperstartling Stiffness, and Accidental Falls
Neurol 88:e38-e41, Russo, S.P.,et al, 2017
Acute Hydrocephalus Caused by Radiographically Occult Fourth Ventricular Outlet Obstruction
Neurol 88:e36-e37, Duran, D.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
A Woman in her 40s with Headache and New-Onset Seizures
JAMA Neurol 74:476-480, Graham, M.S.,et al, 2017
Neurological Autoantibody Prevalence in Epilepsy on Unknown Etiology
JAMA Neurol 74:397-402,384, Dubey, D.,et al, 2017
Association of Spinal Manipulative Therapy with Clinical Benefit and Harm for Acute Low Back Pain
JAMA 317:1451-1460,1418, Paige, N.M.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
Morvan Syndrome as a Paraneoplastic Disorder of Thymoma with Anti-CASPR2 antibodies
Lancet 389:1367-1368, Vale, T.C.,et al, 2017
Acute Spinal Cord Compression
NEJM 376:1358-1369, Ropper, A.E. & Ropper, A.H., 2017
Two-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke
NEJM 376:1341-1349, Van Den Berg, L.A.,et al, 2017
Reversible Gait Ataxia
Neurol 88:e145-e149, Abkur, T.M. & Bede, P., 2017
Reduction in Time to Treatment in Prehospital Telemedicine Evaluation and Thrombolysis
Neurol 88:1305-1312, Taqui, A.,et al, 2017
Intracranial Dural Arteriovenous Fistulae
Stroke 48:1424-1431, Reynolds, M.R.,et al, 2017
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy
Stroke 48:1416-1419, Labovitz, D.L.,et al, 2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017